{"id":1068421,"date":"2024-01-20T02:36:23","date_gmt":"2024-01-20T07:36:23","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/coherus-presents-positive-phase-2-clinical-data-on-casdozokitug-a-first-in-class-il-27-targeted-antibody-at-the-2024-asco-gi-cancers-symposium\/"},"modified":"2024-08-18T11:47:05","modified_gmt":"2024-08-18T15:47:05","slug":"coherus-presents-positive-phase-2-clinical-data-on-casdozokitug-a-first-in-class-il-27-targeted-antibody-at-the-2024-asco-gi-cancers-symposium","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/coherus-presents-positive-phase-2-clinical-data-on-casdozokitug-a-first-in-class-il-27-targeted-antibody-at-the-2024-asco-gi-cancers-symposium.php","title":{"rendered":"Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium"},"content":{"rendered":"<p><![CDATA[\u2013 Data demonstrate early activity with casdozokitug\/atezolizumab\/bevacizumab; 38% objective response rate including three complete responses \u2013]]><\/p>\n<p>Excerpt from:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/01\/18\/2811956\/0\/en\/Coherus-Presents-Positive-Phase-2-Clinical-Data-on-Casdozokitug-a-First-in-Class-IL-27-Targeted-Antibody-at-the-2024-ASCO-GI-Cancers-Symposium.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium\">Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Excerpt from: Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/coherus-presents-positive-phase-2-clinical-data-on-casdozokitug-a-first-in-class-il-27-targeted-antibody-at-the-2024-asco-gi-cancers-symposium.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068421","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068421"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068421"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068421\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}